Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDArrowhead Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 9 | -$0.26 | -$0.11 | -$0.19 |
| Q2 2025 | 12 | -$1.12 | -$0.25 | -$0.95 |
| Q3 2025 | 9 | -$1.16 | $0.62 | -$0.11 |
| Q4 2025 | 6 | -$0.00 | $0.28 | $0.11 |
| Q1 2026 | 5 | -$1.87 | $0.40 | -$0.95 |
| Q2 2026 | 1 | -$3.16 | $0.23 | -$1.27 |
| Q3 2026 | 1 | -$3.23 | $0.24 | -$1.30 |
| Q4 2026 | 1 | -$2.91 | $0.21 | -$1.17 |
| Q1 2027 | 1 | -$3.21 | $0.24 | -$1.29 |
| Q2 2027 | 1 | -$3.26 | $0.24 | -$1.31 |
| Q3 2027 | 1 | -$2.12 | $0.16 | -$0.86 |
Arrowhead Pharmaceuticals, Inc. Earnings Date And Information
Arrowhead Pharmaceuticals, Inc. last posted its earnings results on Tuesday, November 25th, 2025. The company reported $-0.18 earnings per share for the quarter, missing analysts' consensus estimates of $-0.11157 by $0.06843. The company had revenue of 27.77 M for the quarter and had revenue of 829.45 M for the year. Arrowhead Pharmaceuticals, Inc. has generated $0 earnings per share over the last year ($-0.01 diluted earnings per share) and currently has a price-to-earnings ratio of -64.27. Arrowhead Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 26th, 2025 based on prior year's report dates.
Arrowhead Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 08/07/2025 | Q3 2025 | -$0.94 | -$1.26 | -0.32 | $46.83 M | $27.77 M |
| 05/12/2025 | Q2 2025 | -$0.06 | $2.78 | 2.84 | N/A | $542.71 M |
| 02/10/2025 | Q1 2025 | -$0.42 | -$1.39 | -0.97 | N/A | $2.50 M |
| 11/26/2024 | Q4 2024 | -$1.05 | -$1.40 | -0.35 | $55.07 M | $23.59 M |
| 08/08/2024 | Q3 2024 | -$0.58 | -$1.38 | -0.8 | $52.87 M | $0 |
| 05/09/2024 | Q2 2024 | -$0.06 | -$1.02 | -0.96 | N/A | $0 |
| 02/06/2024 | Q1 2024 | -$0.78 | -$1.24 | -0.46 | N/A | $3.55 M |
| 11/29/2023 | Q4 2023 | -$0.70 | -$1.02 | -0.32 | $44.63 M | $16.10 M |
| 08/07/2023 | Q3 2023 | -$0.58 | -$0.96 | -0.38 | $45.42 M | $15.83 M |
| 05/02/2023 | Q2 2023 | -$0.64 | $0.46 | 1.1 | $45.48 M | $146.27 M |
| 02/06/2023 | Q1 2023 | $1.14 | -$0.39 | -1.53 | $162.52 M | $62.55 M |
| 11/28/2022 | Q4 2022 | -$0.57 | -$0.81 | -0.24 | $50.30 M | $31.58 M |
| 08/04/2022 | Q3 2022 | -$0.45 | -$0.67 | -0.22 | $45.75 M | $32.41 M |
| 05/10/2022 | Q2 2022 | -$0.08 | $0.42 | 0.5 | $122.15 M | $151.81 M |
| 02/02/2022 | Q1 2022 | -$0.22 | -$0.60 | -0.38 | $47.81 M | $27.44 M |
| 11/22/2021 | Q4 2021 | -$0.11 | -$0.61 | -0.5 | $42.19 M | $38.28 M |
| 08/05/2021 | Q3 2021 | -$0.08 | -$0.29 | -0.21 | $43.47 M | $45.89 M |
| 05/04/2021 | Q2 2021 | -$0.09 | -$0.26 | -0.17 | $39.42 M | $32.81 M |
| 02/04/2021 | Q1 2021 | $1.00 | -$0.20 | -1.2 | $106.12 M | $21.30 M |
| 11/23/2020 | Q4 2020 | $0.34 | -$0.47 | -0.81 | $57.76 M | $7.63 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Arrowhead Pharmaceuticals, Inc. Earnings: FAQ's
Arrowhead Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, November 26th, 2025 based offlast year's report dates.
The conference call for Arrowhead Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Arrowhead Pharmaceuticals, Inc.'s latest earnings report can be read online.
Arrowhead Pharmaceuticals, Inc. (:ARWR) has a recorded annual revenue of $829.45 M.
Arrowhead Pharmaceuticals, Inc. (:ARWR) has a recorded net income of $-1,631,000.Arrowhead Pharmaceuticals, Inc. has generated $-0.01 earnings per share over the last four quarters.
Arrowhead Pharmaceuticals, Inc. (:ARWR) has a price-to-earnings ratio of -64.27 and price/earnings-to-growth ratio is -7.44.